CLINUVEL PHARMACEUTICALS LTD

Clinuvel Pharmaceuticals’ share fell 1.1% to AUD 7.03, trading below its 200‑day MA yet above the 52‑week low, as investors weigh its UV‑focused dermatology pipeline.

Clinuvel Pharmaceuticals: FDA‑cleared cannabinoid therapy for ASD & Rett, Phase II/III progress, strong IP, and a $379 m market cap—watch its next data readout.